IL156479A0 - Substituted-8-arylquinoline phosphodiesterase-4 inhibitors - Google Patents

Substituted-8-arylquinoline phosphodiesterase-4 inhibitors

Info

Publication number
IL156479A0
IL156479A0 IL15647901A IL15647901A IL156479A0 IL 156479 A0 IL156479 A0 IL 156479A0 IL 15647901 A IL15647901 A IL 15647901A IL 15647901 A IL15647901 A IL 15647901A IL 156479 A0 IL156479 A0 IL 156479A0
Authority
IL
Israel
Prior art keywords
inhibitors
substituted
arylquinoline
phosphodiesterase
arylquinoline phosphodiesterase
Prior art date
Application number
IL15647901A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of IL156479A0 publication Critical patent/IL156479A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15647901A 2000-12-20 2001-12-14 Substituted-8-arylquinoline phosphodiesterase-4 inhibitors IL156479A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25680300P 2000-12-20 2000-12-20
PCT/US2001/048674 WO2002069970A1 (en) 2000-12-20 2001-12-14 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Publications (1)

Publication Number Publication Date
IL156479A0 true IL156479A0 (en) 2004-01-04

Family

ID=22973639

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15647901A IL156479A0 (en) 2000-12-20 2001-12-14 Substituted-8-arylquinoline phosphodiesterase-4 inhibitors

Country Status (28)

Country Link
US (1) US6740666B2 (de)
EP (1) EP1363635B1 (de)
JP (1) JP2004521921A (de)
KR (1) KR20030063456A (de)
CN (1) CN100508978C (de)
AR (1) AR035514A1 (de)
AT (1) ATE428420T1 (de)
AU (1) AU2001297603B2 (de)
BG (1) BG107900A (de)
BR (1) BR0116372A (de)
CA (1) CA2431549A1 (de)
CZ (1) CZ20031738A3 (de)
DE (1) DE60138421D1 (de)
DO (1) DOP2001000308A (de)
EA (1) EA006607B1 (de)
EE (1) EE200300266A (de)
HU (1) HUP0400654A3 (de)
IL (1) IL156479A0 (de)
JO (1) JO2317B1 (de)
MX (1) MXPA03005673A (de)
MY (1) MY136792A (de)
NO (1) NO20032807L (de)
NZ (1) NZ526376A (de)
PE (1) PE20020787A1 (de)
PL (1) PL362564A1 (de)
SK (1) SK7732003A3 (de)
WO (1) WO2002069970A1 (de)
ZA (1) ZA200304672B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116231A (pt) * 2000-12-20 2004-03-02 Merck & Co Inc Método de formação de uma mistura do produto de reação
US7144896B2 (en) 2002-03-18 2006-12-05 Merck Frosst Canada Ltd. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
CA2515407A1 (en) * 2003-02-10 2004-08-26 Todd Ovokaitys Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
CN100425591C (zh) * 2005-09-26 2008-10-15 山东大学 含有磺酰基二苯基乙烯桥化合物及其制法和药物应用
EP1976495A2 (de) * 2006-01-06 2008-10-08 Aarhus Universitet Auf den serotonin-transporter wirkende verbindungen
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
WO2008006050A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
EP2674417A3 (de) * 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl-PDE4-Inhibitoren zur Behandlung von Entzündungen
RU2012117141A (ru) * 2009-10-01 2013-11-10 Алькон Рисерч, Лтд. Композиции олопатадина и способы их применения
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
US12472241B2 (en) 2018-12-28 2025-11-18 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors
US20240199661A1 (en) * 2021-03-31 2024-06-20 Riboscience Llc Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
ES2092729T3 (es) 1992-07-01 1996-12-01 Hoechst Ag Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
DE4306152A1 (de) 1993-02-27 1994-09-01 Hoechst Ag Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
ATE260911T1 (de) 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326699D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0765867A1 (de) 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19622370A1 (de) 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
ES2202663T3 (es) 1996-12-11 2004-04-01 ABBOTT GMBH & CO. KG Cetobenzamidas como inhibidores de calpaina.
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
JP4415360B2 (ja) 2000-01-28 2010-02-17 エプソントヨコム株式会社 縦結合弾性表面波フィルタ

Also Published As

Publication number Publication date
MXPA03005673A (es) 2003-10-06
SK7732003A3 (en) 2003-11-04
ZA200304672B (en) 2004-04-21
CN100508978C (zh) 2009-07-08
US20020143032A1 (en) 2002-10-03
EA200300706A1 (ru) 2003-12-25
HUP0400654A3 (en) 2011-07-28
NO20032807L (no) 2003-08-15
CZ20031738A3 (cs) 2003-11-12
HUP0400654A2 (hu) 2004-06-28
DE60138421D1 (en) 2009-05-28
WO2002069970A1 (en) 2002-09-12
JP2004521921A (ja) 2004-07-22
PL362564A1 (en) 2004-11-02
MY136792A (en) 2008-11-28
PE20020787A1 (es) 2002-09-10
KR20030063456A (ko) 2003-07-28
BR0116372A (pt) 2003-12-09
BG107900A (bg) 2004-06-30
ATE428420T1 (de) 2009-05-15
AR035514A1 (es) 2004-06-02
EP1363635A1 (de) 2003-11-26
NZ526376A (en) 2005-02-25
US6740666B2 (en) 2004-05-25
EE200300266A (et) 2003-10-15
EP1363635B1 (de) 2009-04-15
DOP2001000308A (es) 2002-07-15
AU2001297603B2 (en) 2006-02-16
CN1551769A (zh) 2004-12-01
CA2431549A1 (en) 2002-09-12
JO2317B1 (en) 2005-09-12
EA006607B1 (ru) 2006-02-24
NO20032807D0 (no) 2003-06-19

Similar Documents

Publication Publication Date Title
IL160213A0 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
GB9900416D0 (en) Inhibitors
AU3704101A (en) Kinase inhibitors
IL146518A0 (en) Metalloprotease inhibitors
IL156064A0 (en) Vla-4 inhibitors
AU3408801A (en) Tnf-alpha inhibitors
EP1324759A4 (de) Nf--g(k)b inhibitoren
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
IL150114A0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
PL362564A1 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
PL350452A1 (en) Dihetero-substituted metalloprotease inhibitors
GB0015562D0 (en) Heterocycles
AU5884101A (en) Heterocyclic compounds
GB0030284D0 (en) Enzyme inhibitors
EP1153022A4 (de) Protease inhibitoren
AU7635401A (en) Hetaryl-substituted heterocycles
GB0009479D0 (en) Antihistaminic compounds
GB0029730D0 (en) Inhibitors
GB0029733D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors
GB0021193D0 (en) Inhibitors
GB0101135D0 (en) Inhibitors
GB0128453D0 (en) Inhibitors
GB0101134D0 (en) Inhibitors